The first 250 prescriptions for each medicine would be reviewed by a human doctor in the Utah trial after being sent to a pharmacy, Doctronic added.

The company told Australian Doctor that a bespoke malpractice insurance policy covered any harms caused by AI.

Patients would pay $ 6 AUD per“ consultation”, which Doctronic said covered the cost of identity verification and retrieval of the patient’ s electronic health record.

It said the AI then asked whether the treatment was working, checked past medical history with the patient and asked about side effects and allergies to assess if a refill was appropriate.

It would also check the patient’ s clinical record for other scripts with potential interactions, Doctronic said.

If the AI identified any concerns, it would refer the patient to a human doctor, but if not, it would send the script electronically to the patient’ s nominated pharmacy to be filled.

Clinically proven to:* 1

Reduce total acne lesions by

in 24 weeks

5.8 % incidence of treatment-emergent adverse events. The most common event(> 1 %) was skin tightness( 1.7 %), and all events were mild to moderate.* 1

TREAT | REDUCE | PREVENT

Bella Rough INCREASED bladder cancer mortality in colourblind patients is potentially because they cannot see blood in their urine, researchers suggest.

Their study of US health records showed a 52 % lower 20-year survival rate in 135 patients with colour vision deficiency( CVD) and bladder cancer compared with matched controls with only bladder cancer after adjusting for comorbidities and baseline characteristics.

Blood in urine is the sentinel sign of bladder cancer.

Not an actual patient. Image has been digitally altered to represent a patient advanced in their journey towards clear skin.

AKLIEF( trifarotene 50 µ g / g) Cream is indicated for the topical treatment of acne vulgaris of the face and / or the trunk in patients from 12 years of age and older, when many comedones, papules and / or pustules are present. 2

* Results from a randomised, split-face, double-blind study of patients aged 17 – 34 years( N = 121) with moderate-to-severe facial acne and acne scars treated with AKLIEF Cream or vehicle once daily for 24 weeks. At Week 1, the reduction in total acne lesion counts from baseline was significantly greater with AKLIEF Cream vs vehicle( P = 0.0097). At Week 24, the percentage reduction in mean total acne lesion count was 70.0 %( from baseline: 37.3) with AKLIEF Cream vs 44.9 %( from baseline: 37.3) with vehicle( nominal P < 0.05), and the reduction in total atrophic acne scar count was 5.9 from baseline with AKLIEF Cream vs 2.7 with vehicle( P < 0.0001, primary endpoint). 1 The START clinical trial was sponsored by Galderma. 1 References: 1. Schleicher S et al. Dermatol Ther( Heidelb) 2023; 13( 12): 3085 – 3096. 2. AKLIEF( trifarotene 50 µ g / g) Cream Product Information.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

PBS Information: AKLIEF( trifarotene 50 µ g / g) Cream is not listed on the PBS.

Find out more

Please review the full Product Information before prescribing, available on request from Galderma Medical Information on 1800 800 765, at galderma. com / au / sites / default / files / Aklief _ PI _ 181124. pdf or by scanning the QR code.

Galderma Australia Pty Ltd. Level 18, 1 Denison Street, North Sydney 2060. ABN 12 003 976 930. Galderma and AKLIEF ® are registered trademarks of Galderma Holding S. A. AU-AFC-260010. AKL-005225-00. SSW. Date of preparation: February 2026.

Blood in urine is the sentinel sign of bladder cancer for 80-90 % of patients who present with painless gross haematuria, the US researchers wrote in Nature Health last month.

“ The majority of CVDs impair the ability to distinguish the colour red, leading to the possibility of delayed recognition of malignancy and an increased risk of severe disease among patients with CVD and colorectal cancer or bladder cancer,” they wrote.

The study did not show significantly different survival outcomes for patients with CVD and colorectal cancer compared with controls, which they attributed to the wider range of early symptoms and the structured screening programs.

They acknowledged that the small study was only“ hypothesis generating” but said it should still“ increase clinicians’ suspicion of bladder cancer among patients with CVD and non-specific signs of malignancy”.

Nat Health 2026; 15 Jan.